United States v. Boston Scientific Corporation
GPTKB entity
Statements (96)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
legal case
|
| gptkbp:analyzes |
whistleblower complaint
|
| gptkbp:approves |
court approval
court approval required |
| gptkbp:caseOutcome |
settlement reached
|
| gptkbp:caseTypes |
civil case
healthcare fraud enforcement 1:06-cv-00001 1:06-cv-10000 |
| gptkbp:claims |
fraudulent marketing practices
|
| gptkbp:community_engagement |
increased awareness
healthcare integrity |
| gptkbp:condition |
monitoring compliance
|
| gptkbp:corporateSocialResponsibility |
policy changes
|
| gptkbp:court |
gptkb:United_States
gptkb:Boston_Scientific_Corporation civil fines imposed denied allegations upheld regulations |
| gptkbp:date |
December 2006
March 15, 2007 |
| gptkbp:decidedBy |
gptkb:United_States_District_Court
|
| gptkbp:duration |
approximately 1 year
approximately 12 months |
| gptkbp:filingDate |
January 2006
January 3, 2006 |
| gptkbp:homeGround |
allegations of misconduct
allegations of kickbacks investigation initiated by whistleblower |
| https://www.w3.org/2000/01/rdf-schema#label |
United States v. Boston Scientific Corporation
|
| gptkbp:impact |
industry standards
healthcare regulations increased scrutiny on medical device companies healthcare_compliance |
| gptkbp:industry |
medical devices
|
| gptkbp:involves |
gptkb:United_States
gptkb:Boston_Scientific_Corporation |
| gptkbp:jurisdiction |
federal court
|
| gptkbp:legal_principle |
medical device regulations
corporate fraud |
| gptkbp:legal_representation |
gptkb:Department_of_Justice
|
| gptkbp:legalStatus |
healthcare_law
|
| gptkbp:legislation |
Affordable Care Act
|
| gptkbp:media_coverage |
significant coverage
|
| gptkbp:notableFeature |
$30 million
regulatory compliance compliance monitoring corporate governance settlement agreement legal scholars business ethics medical ethics public trust in healthcare corporate responsibility negotiated settlement corporate accountability corporate ethics increased oversight corporate compliance programs publicly accessible records court records available compliance program impact on industry standards enhanced regulatory oversight future compliance requirements healthcare industry reforms influence on future litigation. landmark case in healthcare law legal implications for corporations legal strategy employed medical device marketing practices healthcare_fraud healthcare_fraud_prevention |
| gptkbp:outcome |
settlement
financial restitution financial penalties resolved through settlement reform initiatives financial penalties imposed increased penalties for fraud enhanced scrutiny of medical devices financial restitution to government increased penalties for future violations reform in marketing practices reputation management for defendant settlement terms negotiated |
| gptkbp:precedent |
corporate accountability
False Claims Act enforcement |
| gptkbp:regulatoryBody |
gptkb:FDA
|
| gptkbp:related_to |
False Claims Act
|
| gptkbp:relatedPatent |
gptkb:United_States_v._Johnson_&_Johnson
gptkb:United_States_v._Medtronic,_Inc. |
| gptkbp:significance |
regulatory scrutiny
|
| gptkbp:tactics |
dispute allegations
|
| gptkbp:year |
2006
|